

# Balaxi Pharmaceuticals Limited

Date:10.03.2025

To

Sri.Binoy Yohannan,  
Associate Vice President- Surveillance,  
National Stock Exchange of India Limited  
Exchange Palza,Plot No.C-1,Block G,  
Bandra Kurla Complex, Bandra (E),  
MUMBAI-400051

Dear Sir,

**Sub: Clarification on Movement in Price**

**Ref: Symbol: BALAXI**

This is with reference to NSE Letter No: NSE/CM/Surveillance/15252 dated 10.03.2025 with respect to significant movement in price in the scrip of the Company, in the recent past and asking Company to submit response on the same.

In this regard, we would like to inform you that there is no material information/announcement pending with the Company which may have a bearing on the price behavior in the scrip of the Company. The movement in price of our scrip is purely market driven.

We would like to further submit that the Company had been complying with all the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") within the stipulated period from time to time. The Company will adhere to the compliance requirement in terms of SEBI Listing Regulations and keep the exchange informed of all the information in the future as well.

This is for your information and records.

Regards,  
For Balaxi Pharmaceuticals Limited

Mohith Kumar Khandelwal  
Company Secretary & Compliance Officer

**Registered Office:**

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in